# Phase 1 Readiness Checklist and Gate

This checklist is a practical go/no-go framework for transitioning from research to first-in-human trial preparation.

## Usage

1. Assign one accountable owner per workstream.
2. Mark each item as: `NOT_STARTED`, `IN_PROGRESS`, `DONE`, or `BLOCKED`.
3. Attach objective evidence for each item.
4. Run the Go/No-Go gate in the scorecard template at `templates/phase1_go_no_go_scorecard.json`.

## Workstream Owners

- Regulatory Lead: `TBD`
- Clinical Lead: `TBD`
- Medical Safety Lead: `TBD`
- CMC/GMP Lead: `TBD`
- QA Lead: `TBD`
- Bioinformatics/Software Lead: `TBD`
- Data Protection Lead: `TBD`

## Checklist

### 1. Regulatory and Ethics (Owner: Regulatory Lead)

- IND/CTA strategy finalized and documented.
- Pre-IND/scientific advice meeting completed and minutes archived.
- Draft protocol, Investigator Brochure, and informed consent completed.
- IRB/IEC submission package complete.
- Trial registration plan prepared (e.g., ClinicalTrials.gov/EUCTR as applicable).

### 2. CMC/GMP Manufacturing (Owner: CMC/GMP Lead)

- GMP process definition frozen (batch record v1.0).
- Critical quality attributes (CQA) and critical process parameters (CPP) approved.
- Assays validated: identity, purity, potency, sterility, endotoxin.
- Stability program initiated (accelerated + real-time).
- Release specifications approved by QA.
- Deviation/CAPA workflow in place.

### 3. Nonclinical/Preclinical (Owner: Medical Safety Lead)

- GLP toxicology studies complete and reviewed.
- Biodistribution and dose-ranging studies complete.
- Pharmacology/efficacy package complete for target indication.
- Immunogenicity risk and off-target risk assessment documented.

### 4. Clinical Operations (Owner: Clinical Lead)

- Site shortlist and feasibility complete.
- Monitoring plan and safety reporting plan finalized.
- DSMB/Safety governance charter approved.
- Inclusion/exclusion criteria and stopping rules finalized.
- IMP handling, randomization, and accountability process validated.

### 5. Quality and Compliance (Owner: QA Lead)

- GCP/GMP training logs complete for trial-critical staff.
- Document control and versioning process validated.
- Audit trail and change-control process established.
- Inspection-readiness mock audit completed.

### 6. Software, Data, and Security (Owner: Bioinformatics/Software Lead)

- Data integrity and traceability matrix complete.
- Validation package for software-supported decisions complete.
- Access control, encryption, and backup/restore tested.
- Patient data handling aligned with jurisdictional requirements (HIPAA/GDPR/local laws).
- Incident response and business continuity procedures tested.

## Gate Rules (Mandatory)

All items below must be `DONE` to pass:

- Regulatory: IND/CTA strategy, protocol package, IRB/IEC package.
- CMC/GMP: validated assays, release specs, QA approval.
- Nonclinical: GLP tox + biodistribution complete.
- Clinical safety governance: DSMB/safety reporting finalized.

If any mandatory item is not `DONE`, status is `NO_GO`.

## Gate Scoring (Weighted)

- Regulatory and Ethics: 20%
- CMC/GMP: 30%
- Nonclinical/Preclinical: 20%
- Clinical Operations: 15%
- Quality and Compliance: 10%
- Software/Data/Security: 5%

Suggested interpretation:

- Score >= 0.85 and all mandatory items done: `GO`
- Score 0.70-0.84 and all mandatory items done: `CONDITIONAL_GO`
- Score < 0.70 or any mandatory item not done: `NO_GO`

## Evidence Examples

- Signed protocols, meeting minutes, approvals, validation reports.
- SOP references and training records.
- Study reports with dates, versions, and approvers.

---

## Current Project Status Assessment (as of 2026-04-06)

**Overall Status: NO_GO**  
**Weighted Score: 0.0**  
**All mandatory items: NOT STARTED**

### Identified Gaps by Workstream

#### 1. Regulatory and Ethics (Owner: TBD)
- [ ] **IND/CTA strategy** - Not started. Need to define regulatory pathway (FDA IND vs EMA CTA).
- [ ] **Pre-IND/scientific advice meeting** - Not started. No regulatory agency interactions scheduled.
- [ ] **Protocol package** - Not started. No clinical protocol, Investigator Brochure, or informed consent drafted.
- [ ] **IRB/IEC submission package** - Not started. No ethics committee submissions prepared.
- [ ] **Trial registration plan** - Not started. No ClinicalTrials.gov or EUCTR registration planned.

#### 2. CMC/GMP Manufacturing (Owner: TBD)
- [ ] **GMP process definition frozen** - Not started. No batch record v1.0 exists.
- [ ] **CQA/CPP approved** - Not started. Critical quality attributes and process parameters undefined.
- [ ] **Validated assays** - Not started. No validated methods for identity, purity, potency, sterility, endotoxin.
- [ ] **Stability program** - Not started. No accelerated or real-time stability studies initiated.
- [ ] **Release specifications QA approved** - Not started. No QA-approved release criteria.
- [ ] **Deviation/CAPA workflow** - Not started. No quality management system for deviations.

#### 3. Nonclinical/Preclinical (Owner: TBD)
- [ ] **GLP toxicology studies** - Not started. No GLP-compliant toxicology package.
- [ ] **Biodistribution studies** - Not started. No biodistribution or dose-ranging data.
- [ ] **Dose-ranging studies** - Not started. No dose optimization data.
- [ ] **Efficacy package** - Not started. No pharmacology/efficacy data for target indication.
- [ ] **Off-target risk assessment** - Not started. Immunogenicity and off-target risks not fully documented.

#### 4. Clinical Operations (Owner: TBD)
- [ ] **Site feasibility** - Not started. No clinical site identification or feasibility assessment.
- [ ] **Monitoring plan** - Not started. No clinical monitoring or safety reporting plans.
- [ ] **DSMB/safety reporting** - Not started. No Data Safety Monitoring Board charter or safety governance.
- [ ] **Stopping rules** - Not started. Inclusion/exclusion criteria and stopping rules undefined.
- [ ] **IMP accountability** - Not started. Investigational product handling and randomization not validated.

#### 5. Quality and Compliance (Owner: TBD)
- [ ] **GCP/GMP training logs** - Not started. No training records for trial-critical staff.
- [ ] **Document control** - Not started. No versioning or document control process.
- [ ] **Change control** - Not started. No audit trail or change-control process.
- [ ] **Mock audit** - Not started. No inspection-readiness assessment completed.

#### 6. Software, Data, and Security (Owner: TBD)
- [x] **Traceability matrix** - Draft completed. See docs/REQUIREMENTS_TRACEABILITY_MATRIX.md.
- [x] **Software validation package** - Technical validation package completed with IQ technical baseline, OQ evidence, and PQ scenario evidence. See validation/IQ_EVIDENCE_LOG.md, validation/OQ_EVIDENCE_LOG.md, and validation/PQ_Performance_Qualification.md.
- [x] **Security controls tested** - Completed for RBAC, audit controls, and backup/restore in OQ evidence scripts.
- [x] **Privacy compliance** - Technical de-identification checks executed in OQ evidence.
- [x] **Incident response tested** - Technical incident drill simulation executed within thresholds. See validation/evidence/PQ-OPS-02_TS-009_20260406_165304.json.

### Software System Status (Separate from Clinical Readiness)

The **research software system** is functional and validated:
- ✅ All 6 core modules operational (immunogenicity, HLA binding, mRNA optimization, pharmacokinetics, clinical validator, report generator)
- ✅ Successfully processes real cancer mutation data
- ✅ Generates publication-ready research reports
- ⚠️ Classified as **ADVANCED_PRECLINICAL** - suitable for research only

### Path to Clinical Trial Readiness

**Immediate priorities (Months 1-3):**
1. Assign workstream owners (Regulatory Lead, Clinical Lead, CMC/GMP Lead, etc.)
2. Initiate pre-IND meeting with regulatory agency
3. Begin GMP manufacturing process development
4. Start GLP toxicology studies
5. Establish quality management system

**Estimated timeline to Phase 1 readiness: 18-24 months** from project kickoff, assuming adequate funding and resources.
